Haemonetics Corporation: contract revenue excluding tax
Contract revenue excluding tax for Haemonetics Corporation. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Haemonetics Corporation financial histories
What this measure means
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
Exact concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-04-04 to 2026-03-28. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-03-30 | 2026-03-28 | 1,334,027,000 | USD | 2026-05-20 | 10-K · 0000313143-26-000050 |
| 2024-03-31 | 2025-03-29 | 1,360,824,000 | USD | 2026-05-20 | 10-K · 0000313143-26-000050 |
| 2023-04-02 | 2024-03-30 | 1,309,055,000 | USD | 2026-05-20 | 10-K · 0000313143-26-000050 |
| 2022-04-03 | 2023-04-01 | 1,168,660,000 | USD | 2025-05-21 | 10-K · 0000313143-25-000025 |
| 2021-04-04 | 2022-04-02 | 993,196,000 | USD | 2024-05-20 | 10-K · 0000313143-24-000020 |
Related financial histories
- Haemonetics Corporation: total assets
- Haemonetics Corporation: stockholders equity
- Haemonetics Corporation: cash and cash equivalents
- Haemonetics Corporation: net income or loss
- Haemonetics Corporation: operating cash flow
- Haemonetics Corporation: capital expenditure payments
- Haemonetics Corporation: revenue
- Haemonetics Corporation: financing cash flow
- Haemonetics Corporation: investing cash flow
- Haemonetics Corporation: retained earnings or deficit
- Haemonetics Corporation: basic weighted-average shares
- Haemonetics Corporation: diluted weighted-average shares
- Haemonetics Corporation: basic earnings per share
- Haemonetics Corporation: diluted earnings per share
- Haemonetics Corporation: income tax expense or benefit
- Haemonetics Corporation: net property, plant and equipment
- Haemonetics Corporation: share-based compensation expense
- Haemonetics Corporation: operating income or loss
- Haemonetics Corporation: current assets
- Haemonetics Corporation: interest expense
- Haemonetics Corporation: current liabilities
- Haemonetics Corporation: current accounts payable
- Haemonetics Corporation: goodwill carrying amount
- Haemonetics Corporation: net finite-lived intangible assets
- Haemonetics Corporation: net current accounts receivable
- Haemonetics Corporation: common-stock repurchase payments
- Haemonetics Corporation: operating expenses
- Haemonetics Corporation: net inventory
- Haemonetics Corporation: gross profit
- Haemonetics Corporation: selling, general and administrative expense
- Haemonetics Corporation: research and development expense
Inspect the source
- Entity
- Haemonetics Corporation / CIK 0000313143
- Captured
- 2026-09-19T14:55:56.998Z
- SEC response SHA-256
2e33f4ca1a7afeb7423d92ea983bf865e708216490b0c193ce73ffd299c712d1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000313143.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))